News

Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer’s Disease

July 23, 2019

Download PDF

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis

June 13, 2018

Download PDF

Samus Therapeutics Announces Launch of Expanded Clinical Development Programs for Novel Anti-Epichaperome Small Molecules to Diagnose and Treat Cancer and Neurodegenerative Disease

March 30, 2017

Download PDF